11.40
-0.05 (-0.44%)
| Previous Close | 11.45 |
| Open | 11.57 |
| Volume | 443,297 |
| Avg. Volume (3M) | 982,892 |
| Market Cap | 1,190,084,736 |
| Price / Sales | 29.33 |
| Price / Book | 2.43 |
| 52 Weeks Range | |
| Earnings Date | 13 Nov 2025 |
| Operating Margin (TTM) | -583.86% |
| Diluted EPS (TTM) | -11.24 |
| Total Debt/Equity (MRQ) | 18.94% |
| Current Ratio (MRQ) | 3.73 |
| Operating Cash Flow (TTM) | -291.17 M |
| Levered Free Cash Flow (TTM) | -169.99 M |
| Return on Assets (TTM) | -101.07% |
| Return on Equity (TTM) | -247.04% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bullish | Mixed |
| Biotechnology (Global) | Bullish | Mixed | |
| Stock | Alumis Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 2.0 |
| Average | -0.13 |
|
Alumis Inc is a clinical-stage biopharmaceutical company focused on identifying, acquiring, and accelerating the development and commercialization of transformative medicines for autoimmune disorders. The Company leverages its proprietary precision data analytics platform, biological insights, and a team of experts with deep experience in precision medicine drug discovery, development, and immunology, to create medicines that significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 0.63% |
| % Held by Institutions | 53.94% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Ayurmaya Capital Management Company, Lp | 30 Sep 2025 | 15,139,706 |
| Foresite Capital Management V, Llc | 30 Sep 2025 | 5,779,348 |
| Trium Capital Llp | 30 Sep 2025 | 3,122,111 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 40.00 (HC Wainwright & Co., 250.88%) | Buy |
| Median | 33.00 (189.47%) | |
| Low | 32.00 (Leerink Partners, 180.70%) | Buy |
| 32.00 (Guggenheim, 180.70%) | Buy | |
| Average | 35.20 (208.77%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 17.91 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 09 Jan 2026 | 40.00 (250.88%) | Buy | 19.56 |
| 18 Dec 2025 | 20.00 (75.44%) | Buy | 11.06 | |
| Guggenheim | 07 Jan 2026 | 32.00 (180.70%) | Buy | 17.92 |
| Leerink Partners | 07 Jan 2026 | 32.00 (180.70%) | Buy | 17.92 |
| Morgan Stanley | 07 Jan 2026 | 33.00 (189.47%) | Buy | 17.92 |
| Wells Fargo | 06 Jan 2026 | 39.00 (242.11%) | Buy | 16.23 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Jan 2026 | Announcement | Alumis Announces Closing of Upsized Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares |
| 07 Jan 2026 | Announcement | Alumis Announces Pricing of Upsized Public Offering of Common Stock |
| 06 Jan 2026 | Announcement | Alumis Announces Proposed Public Offering of Common Stock |
| 06 Jan 2026 | Announcement | Alumis’ Envudeucitinib Delivers Leading Skin Clearance Among Next-Generation Oral Plaque Psoriasis Therapies in Phase 3 Program |
| 05 Jan 2026 | Announcement | Alumis to Host Conference Call and Webcast to Report Phase 3 ONWARD Topline Data for Envudeucitinib in Moderate-to-Severe Plaque Psoriasis |
| 13 Nov 2025 | Announcement | Alumis Reports Third Quarter 2025 Financial Results and Highlights Recent Progress |
| 04 Nov 2025 | Announcement | Alumis to Participate in Upcoming November Investor Conferences |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |